ChemicalBook > CAS DataBase List > JNJ-38877605
JNJ-38877605
- Product Name
- JNJ-38877605
- CAS No.
- 943540-74-7
- Chemical Name
- JNJ-38877605
- Synonyms
- JNJ;OMO-1);JNJ-38877618;JNJ-38877618 (OMO1;Venadaparib Impurity 21;JNJ-38877618,Inhibitor,c-Met/HGFR,JNJ 38877618,JNJ38877618,inhibit;6-[Difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline;6-(difluoro(6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline;Quinoline, 6-[difluoro[6-(4-pyridinyl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]-
- CBNumber
- CB24660859
- Molecular Formula
- C20H12F2N6
- Formula Weight
- 374.35
- MOL File
- 943540-74-7.mol
More
Less
JNJ-38877605 Property
- storage temp.
- Store at -20°C
- solubility
- DMSO : 5 mg/mL (13.36 mM)
More
Less
N-Bromosuccinimide Price
ChemScene
- Product number
- CS-0034063
- Product name
- JNJ-38877618
- Purity
- 99.01%
- Packaging
- 50mg
- Price
- $910
- Updated
- 2021/12/16
ChemScene
- Product number
- CS-0034063
- Product name
- JNJ-38877618
- Purity
- 99.01%
- Packaging
- 100mg
- Price
- $1300
- Updated
- 2021/12/16
ChemScene
- Product number
- CS-0034063
- Product name
- JNJ-38877618
- Purity
- 99.01%
- Packaging
- 5mg
- Price
- $210
- Updated
- 2021/12/16
ChemScene
- Product number
- CS-0034063
- Product name
- JNJ-38877618
- Purity
- 99.01%
- Packaging
- 10mg
- Price
- $310
- Updated
- 2021/12/16
DC Chemicals
- Product number
- DC21440
- Product name
- JNJ-38877618
- Purity
- >98%
- Packaging
- 100mg
- Price
- $800
- Updated
- 2021/12/16
More
Less
JNJ-38877605 Chemical Properties,Usage,Production
Biological Activity
JNJ-38877618 (OMO-1) is a potent, highly selective, and orally bioavailable Met (c-Met) kinase inhibitor with a Kd of 1.4 nM. Its IC50 values for wild-type Met (c-Met) and mutant Met (c-Met) (M1268T) were 2 nM and 3 nM, respectively.
in vivo
In vivo, JNJ-38877618(OMO-1) completely inhibited tumor growth in 3 tumor models: SNU5 MET amp gastric cancer model, U87-MG HGF autocrine glioblastoma model, and exon 14 skipping deletion mutation Hs746T gastric cancer model of MET gene. Administration of OMO-1 in combination with other drugs is well tolerated and can improve and enhance the effect of EGFR-targeted therapy. Although single-agent OMO-1 has no effect on NSCLC HCC827 EGFR, its combination with erlotinib can delay tumor recurrence.
target
| Target | Value |
| Met (Cell-free assay) | 2 nM |
| MET (M1268T) (Cell-free assay) | 3 nM |